SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia

British Journal of Haematology

Volumn 166, Issue 6, 2014, Pages 862-874

  Frolova, Olga ^a   Benito, Juliana ^a   Brooks, Chris ^b   Wang, Rui Yu ^a   Korchin, Borys ^a   Rowinsky, Eric K ^b   Cortes, Jorge ^a   Kantarjian, Hagop ^a   Andreeff, Michael ^a   Frankel, Arthur E ^c   Konopleva, Marina ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Stemline Therapeutics Inc   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Chronic myeloid leukaemia; Interleukin 3 receptor; Leukaemic stem cells; SL 401; SL 501

Indexed keywords

ANTILEUKEMIC AGENT; BCR ABL PROTEIN; BOSUTINIB; CD123 ANTIGEN; CD38 ANTIGEN; CYTARABINE; DASATINIB; IMATINIB; INTERLEUKIN 3 RECEPTOR; NILOTINIB; REBASTINIB; SL 401; SL 501; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLAST CELL CRISIS; CANCER INHIBITION; CANCER STEM CELL; CANCER SURVIVAL; CD34 SELECTION; CELL VIABILITY; CHRONIC MYELOID LEUKEMIA; CLONOGENIC ASSAY; COLONY FORMATION; COLONY FORMING CELL; CONTROLLED STUDY; CYTOGENETICS; DRUG CYTOTOXICITY; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; STEM CELL; SURVIVAL TIME;

CHRONIC MYELOID LEUKAEMIA; INTERLEUKIN-3 RECEPTOR; LEUKAEMIC STEM CELLS; SL-401; SL-501;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; INTERLEUKIN-3 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, MYELOID, CHRONIC-PHASE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; PIPERAZINES; PYRIMIDINES; RECEPTORS, INTERLEUKIN-3; RECOMBINANT FUSION PROTEINS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 84907597109     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12978     Document Type: Article

References (49)

1. Ailles, L.E., Gerhard, B. & Hogge, D.E. (1997) Detection and characterization of primitive malignant and normal progenitors in patients with acute myelogenous leukemia using long-term coculture with supportive feeder layers and cytokines. Blood, 90, 2555-2564.
2. Aldinucci, D., Olivo, K., Lorenzon, D., Poletto, D., Gloghini, A., Carbone, A. & Pinto, A. (2005) The role of interleukin-3 in classical Hodgkin's disease. Leukemia & Lymphoma, 46, 303-311.
3. Angstreich, G.R., Matsui, W., Huff, C.A., Vala, M.S., Barber, J., Hawkins, A.L., Griffin, C.A., Smith, B.D. & Jones, R.J. (2005) Effects of imatinib and interferon on primitive chronic myeloid leukaemia progenitors. British Journal of Haematology, 130, 373-381.
4. Bedi, A., Zehnbauer, B.A., Collector, M.I., Barber, J.P., Zicha, M.S., Sharkis, S.J. & Jones, R.J. (1993) BCR-ABL gene rearrangement and expression of primitive hematopoietic progenitors in chronic myeloid leukemia. Blood, 81, 2898-2902.
5. Berman, E., Nicolaides, M., Maki, R.G., Fleisher, M., Chanel, S., Scheu, K., Wilson, B.A., Heller, G. & Sauter, N.P. (2006) Altered bone and mineral metabolism in patients receiving imatinib mesylate. The New England Journal of Medicine, 354, 2006-2013.
6. Bhatia, R., Holtz, M., Niu, N., Gray, R., Snyder, D.S., Sawyers, C.L., Arber, D.A., Slovak, M.L. & Forman, S.J. (2003) Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood, 101, 4701-4707.
7. Borthakur, A. & Reddy, R. (2010) Imaging cartilage physiology. Topics in Magnetic Resonance Imaging: TMRI, 21, 291-296.
8. Chou, T.C. & Talalay, P. (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation, 22, 27-55.
9. Cohen, K.A., Liu, T.F., Cline, J.M., Wagner, J.D., Hall, P.D. & Frankel, A.E. (2004) Toxicology and pharmacokinetics of DT388IL3, a fusion toxin consisting of a truncated diphtheria toxin (DT388) linked to human interleukin 3 (IL3), in cynomolgus monkeys. Leukemia & Lymphoma, 45, 1647-1656.
10. Copland, M., Hamilton, A., Elrick, L.J., Baird, J.W., Allan, E.K., Jordanides, N., Barow, M., Mountford, J.C. & Holyoake, T.L. (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML, but does not eliminate the quiescent fraction. Blood, 107, 4532-4539.
11. Corbin, A.S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M.W. & Druker, B.J. (2011) Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. The Journal of Clinical Investigation, 121, 396-409.
12. Djokic, M., Bjorklund, E., Blennow, E., Mazur, J., Soderhall, S. & Porwit, A. (2009) Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia. Haematologica, 94, 1016-1019.
13. Engel, H., Goodacre, A., Keyhani, A., Jiang, S., Van, N.T., Kimmel, M., Sanchez-Williams, G. & Andreeff, M. (1997) Minimal residual disease in acute myelogenous leukaemia and myelodysplastic syndromes: a follow-up of patients in clinical remission. British Journal of Haematology, 99, 64-75.
14. Feuring-Buske, M., Frankel, A.E., Alexander, R.L., Gerhard, B. & Hogge, D.E. (2002) A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors. Cancer Research, 62, 1730-1736.
15. Florian, S., Sonneck, K., Hauswirth, A.W., Krauth, M.T., Schernthaner, G.H., Sperr, W.R. & Valent, P. (2006) Detection of molecular targets on the surface of CD34+/CD38- stem cells in various myeloid malignancies. Leukemia & Lymphoma, 47, 207-222.
16. Frankel, A.E., Hall, P.D., Burbage, C., Vesely, J., Willingham, M., Bhalla, K. & Kreitman, R.J. (1997) Modulation of the apoptotic response of human myeloid leukemia cells to a diphtheria toxin granulocyte-macrophage colony-stimulating factor fusion protein. Blood, 90, 3654-3661.
17. Frankel, A.E., McCubrey, J.A., Miller, M.S., Delatte, S., Ramage, J., Kiser, M., Kucera, G.L., Alexander, R.L., Beran, M., Tagge, E.P., Kreitman, R.J. & Hogge, D.E. (2000a) Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias. Leukemia, 14, 576-585.
18. Frankel, A.E., Ramage, J., Kiser, M., Alexander, R., Kucera, G. & Miller, M.S. (2000b) Characterization of diphtheria fusion proteins targeted to the human interleukin-3 receptor. Protein Engineering, 13, 575-581.
19. Frankel, A., Liu, J.S., Rizzieri, D. & Hogge, D. (2008) Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia. Leukaemia & Lymphoma, 49, 543-553.
20. Frankel, A., Woo, J.H., Mauldin, J.P., Carraway, H.E., Frankfurt, O., Forman, S.J., Vasu, S., Pemmaraju, N., Konopleva, M., Hogge, D.E., Garanache-Ottou, F., Angelot-Delettre, F., Brooks, C., Szarek, M., Bergstein, I. & Rowinsky, E. (2013) An update on the robust clinical activity of SL-401, a targeted therapy directed to the interleukin-3 receptor on cancer stem cells and tumor bulk, in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Blood, 122, 2682.
21. Giles, F., O'Brien, S., Cortes, J., Verstovsek, S., Bueso-Ramos, C., Shan, J., Pierce, S., Garcia-Manero, G., Keating, M. & Kantarjian, H. (2005) Outcome of patients with acute myelogenous leukemia after second salvage therapy. Cancer, 104, 547-554.
22. Gill, S., Tasian, S.K., Ruella, M., Shestova, O., Li, Y., Porter, D.L., Carroll, M., Danet-Desnoyers, G., Scholler, J., Grupp, S.A., June, C.H. & Kalos, M. (2014) Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood, 123, 2343-2354.
23. Gorre, M.E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P.N. & Sawyers, C.L. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science, 293, 876-880.
24. Graf, M., Hecht, K., Reif, S., Pelka-Fleischer, R., Pfister, K. & Schmetzer, H. (2004) Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies. European Journal of Haematology, 72, 89-106.
25. Graham, S.M., Jorgensen, H.G., Allan, E., Pearson, C., Alcorn, M.J., Richmond, L. & Holyoake, T.L. (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood, 99, 319-325.
26. Guilhot, F., Druker, B., Larson, R.A., Gathmann, I., So, C., Waltzman, R. & O'Brien, S.G. (2009) High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial. Haematologica, 94, 1669-1675.
27. Hogge, D.E., Yalcintepe, L., Wong, S.H., Gerhard, B. & Frankel, A.E. (2006) Variant diphtheria toxin-interleukin-3 fusion proteins with increased receptor affinity have enhanced cytotoxicity against acute myeloid leukemia progenitors. Clinical Cancer Research, 12, 1284-1291.
28. Holyoake, T., Jiang, X., Eaves, C. & Eaves, A. (1999) Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood, 94, 2056-2064.
29. Jamieson, C.H., Ailles, L.E., Dylla, S.J., Muijtjens, M., Jones, C., Zehnder, J.L., Gotlib, J., Li, K., Manz, M.G., Keating, A., Sawyers, C.L. & Weissman, I.L. (2004) Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. The New England Journal of Medicine, 351, 657-667.
30. Jiang, G., Yang, F., Li, M., Weissbecker, K., Price, S., Kim, K.C., La Russa, V.F., Safah, H. & Ehrlich, M. (2003) Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes. Cancer Biology & Therapy, 2, 103-108.
31. Jordan, C.T., Upchurch, D., Szilvassy, S.J., Guzman, M.L., Howard, D.S., Pettigrew, A.L., Meyerrose, T., Rossi, R., Grimes, B., Rizzieri, D.A., Luger, S.M. & Phillips, G.L. (2000) The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells. Leukemia, 14, 1777-1784.
32. Jorgensen, H.G., Allan, E.K., Jordanides, N.E., Mountford, J.C. & Holyoake, T.L. (2007) Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood, 109, 4016-4019.
33. Keating, A., Wang, X.H. & Laraya, P. (1994) Variable transcription of BCR-ABL by Ph+ cells arising from hematopoietic progenitors in chronic myeloid leukemia. Blood, 83, 1744-1749.
34. Kim, H.P., Frankel, A.E. & Hogge, D.E. (2010) A diphtheria toxin interleukin-3 fusion protein synergizes with tyrosine kinase inhibitors in killing leukemic progenitors from BCR/ABL positive acute leukemia. Leukemia Research, 34, 1035-1042.
35. Kiser, M., McCubrey, J.A., Steelman, L.S., Shelton, J.G., Ramage, J., Alexander, R.L., Kucera, G.L., Pettenati, M., Willingham, M.C., Miller, M.S. & Frankel, A.E. (2001) Oncogene-dependent engraftment of human myeloid leukemia cells in immunosuppressed mice. Leukemia, 15, 814-818.
36. Konopleva, M., Hogge, D.E., Rizzieri, D.A., Cirrito, T.P., Kornblau, S.M., Borthakur, G., Bivins, C., Garcia-Manero, G., Kadia, T.M., Ravandi, F., Andreeff, M., Cortes, J.E., Hoberman, K., Szarek, M., Rowinsky, E., Bergstein, I., Kantarjian, H.M. & Frankel, A.E. (2012) SL-401, a targeted therapy directed to the interleukin-3 receptor present on leukemia blasts and cancer stem cells, is active as a single agent in patients with advanced AML. Blood, 120, [Abstr 3625].
37. Lhermitte, L., de Labarthe, A., Dupret, C., Lapillonne, H., Millien, C., Landman-Parker, J., Hermine, O., Baruchel, A., Sigaux, F., Macintyre, E. & Asnafi, V. (2006) Most immature T-ALLs express Ra-IL3 (CD123): possible target for DT-IL3 therapy. Leukemia, 20, 1908-1910.
38. Liu, T.F., Urieto, J.O., Moore, J.E., Miller, M.S., Lowe, A.C., Thorburn, A. & Frankel, A.E. (2004) Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity. Experimental Hematology, 32, 277-281.
39. Nievergall, E., Ramshaw, H.S., Yong, A.S., Biondo, M., Busfield, S.J., Vairo, G., Lopez, A.F., Hughes, T.P., White, D.L. & Hiwase, D.K. (2014) Monoclonal antibody targeting of IL-3 receptor alpha with CSL362 effectively depletes CML progenitor and stem cells. Blood, 123, 1218-1228.
40. Radich, J.P., Dai, H., Mao, M., Oehler, V., Schelter, J., Druker, B., Sawyers, C., Shah, N., Stock, W., Willman, C.L., Friend, S. & Linsley, P.S. (2006) Gene expression changes associated with progression and response in chronic myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 103, 2794-2799.
41. Ratts, R., Zeng, H., Berg, E.A., Blue, C., McComb, M.E., Costello, C.E., Van der Spek, J.C. & Murphy, J.R. (2003) The cytosolic entry of diphtheria toxin catalytic domain requires a host cell cytosolic translocation factor complex. Journal of Cell Biology, 160, 1139-1150.
42. Ratts, R., Trujillo, C., Bharti, A., van der Spek, J., Harrison, R. & Murphy, J.R. (2005) A conserved motif in transmembrane helix 1 of diphtheria toxin mediates catalytic domain delivery to the cytosol. Proceedings of the National Academy of Sciences of the United States of America, 102, 15635-15640.
43. Ricci, C., Scappini, B., Divoky, V., Gatto, S., Onida, F., Verstovsek, S., Kantarjian, H.M. & Beran, M. (2002) Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line. Cancer Research, 62, 5995-5998.
44. Schiffer, C.A. (2007) BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. The New England Journal of Medicine, 357, 258-265.
45. Su, Y., Li, S.Y., Ghosh, S., Ortiz, J., Hogge, D.E. & Frankel, A.E. (2010) Characterization of variant diphtheria toxin-interleukin-3 fusion protein, DTIL3K116W, for phase I clinical trials. Biologicals, 38, 144-149.
46. Testa, U., Riccioni, R., Militi, S., Coccia, E., Stellacci, E., Samoggia, P., Latagliata, R., Mariani, G., Rossini, A., Battistini, A., Lo-Coco, F. & Peschle, C. (2002) Elevated expression of IL-3Ralpha in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood, 100, 2980-2988.
47. Testa, U., Riccioni, R., Biffoni, M., Diverio, D., Lo-Coco, F., Foa, R., Peschle, C. & Frankel, A.E. (2005) Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression. Blood, 106, 2527-2529.
48. Wang, R.Y., Troncoso, P., Palmer, J.L., El-Naggar, A.K. & Liang, J.C. (1996) Trisomy 7 by dual-color fluorescence in situ hybridization: a potential biological marker for prostate cancer progression. Clinical Cancer Research, 2, 1553-1558.
49. Zhou, B.B., Zhang, H., Damelin, M., Geles, K.G., Grindley, J.C. & Dirks, P.B. (2009) Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nature Reviews. Drug discovery, 8, 806-823.